Literature DB >> 18295728

BAFF, APRIL, TWE-PRIL: who's who?

Capucine Daridon1, Pierre Youinou, Jacques-Olivier Pers.   

Abstract

BAFF and APRIL are two members of the TNF superfamily that have co-stimulatory activity on B cells and contribute to autoimmunity. While BAFF is processed at the cell surface, APRIL is processed inside the cell by a furin-convertase and is able to perform its function only as a soluble factor. However, APRIL can be expressed as a cell surface fusion protein with TWEAK called TWE-PRIL. BAFF can also exist as a soluble molecule and can be detected in human serum. Whether the biological functions controlled by membrane-bound BAFF differ from those triggered by soluble BAFF is unclear. In addition to this complexity, DeltaBAFF, an alternative splice isoform of BAFF shows different properties. BAFF can also, in autoimmune disease form heterotrimers with APRIL but the control and function of these heterotrimers remain unclear. In order to understand the function of these molecules we need to elucidate the complexity of the various forms of these members of the TNF family.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18295728     DOI: 10.1016/j.autrev.2007.05.002

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  16 in total

1.  Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren's syndrome?

Authors:  Gintaras Sudzius; Diana Mieliauskaite; Almantas Siaurys; Rita Viliene; Irena Butrimiene; Dainius Characiejus; Irena Dumalakiene
Journal:  Rheumatol Int       Date:  2013-10-29       Impact factor: 2.631

2.  Intracellular Signaling Pathways in Rheumatoid Arthritis.

Authors:  Charles J Malemud
Journal:  J Clin Cell Immunol       Date:  2013-08-19

Review 3.  The role of B cells in solid organ transplantation.

Authors:  Jean Kwun; Pinar Bulut; Eugenia Kim; Wasim Dar; Byoungchol Oh; Ravi Ruhil; Neal Iwakoshi; Stuart J Knechtle
Journal:  Semin Immunol       Date:  2011-12-01       Impact factor: 11.130

4.  Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis: risk factors for accelerated macrovascular damage?

Authors:  Szilvia Szamosi; Zoltán Csiki; Edit Szomják; Erzsébet Szolnoki; Gabriella Szoke; Zoltán Szekanecz; Gyula Szegedi; Yehuda Shoenfeld; Gabriella Szucs
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

5.  Characterization of Lamprey BAFF-like Gene: Evolutionary Implications.

Authors:  Sabyasachi Das; Yoichi Sutoh; Masayuki Hirano; Qifeng Han; Jianxu Li; Max D Cooper; Brantley R Herrin
Journal:  J Immunol       Date:  2016-08-19       Impact factor: 5.422

6.  BAFF is increased in renal transplant patients following treatment with alemtuzumab.

Authors:  D Bloom; Z Chang; K Pauly; J Kwun; J Fechner; C Hayes; M Samaniego; S Knechtle
Journal:  Am J Transplant       Date:  2009-06-12       Impact factor: 8.086

7.  Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.

Authors:  S Anwar Jagessar; Nicole Heijmans; Luke Oh; Jan Bauer; Erwin L A Blezer; Jon D Laman; Thi-Sau Migone; Matt N Devalaraja; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-30       Impact factor: 4.147

8.  The expression of BAFF, APRIL and TWEAK is altered in eczema skin but not in the circulation of atopic and seborrheic eczema patients.

Authors:  Yunying Chen; Sara Lind Enoksson; Catharina Johansson; Maria A Karlsson; Lena Lundeberg; Gunnar Nilsson; Annika Scheynius; Mikael C I Karlsson
Journal:  PLoS One       Date:  2011-07-13       Impact factor: 3.240

9.  Increased levels of BAFF and APRIL related to human active pulmonary tuberculosis.

Authors:  Kai Liu; Yan Zhang; Shizong Hu; Yang Yu; Qianting Yang; Dongdong Jin; Xinchun Chen; Qi Jin; Haiying Liu
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

10.  BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee; Anna L Travelstead; Jerry A Colliver; Jayne M Ness; Richard M Ransohoff
Journal:  J Neuroinflammation       Date:  2013-01-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.